Serum lipopolysaccharide neutralizing capacity in ischemic stroke.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 06 11 2019
accepted: 21 01 2020
entrez: 22 2 2020
pubmed: 23 2 2020
medline: 6 5 2020
Statut: epublish

Résumé

Periodontitis is associated with increased serum lipopolysaccharide (LPS) activity, which may be one mechanism linking periodontitis with the risk of cardiovascular diseases. As LPS-carrying proteins including lipoproteins modify LPS-activity, we investigated the determinants of serum LPS-neutralizing capacity (LPS-NC) in ischemic stroke. The association of LPS-NC and Aggregatibacter actinomycetemcomitans, a major microbial biomarker in periodontitis, was also investigated. The assay to measure LPS-NC was set up by spiking serum samples with E. coli LPS. The LPS-NC, LPS-binding protein (LBP), soluble CD14 (sCD14), lipoprotein profiles, apo(lipoprotein) A-I, apoB, and phospholipid transfer protein (PLTP) activity, were determined in 98 ischemic stroke patients and 100 age- and sex-matched controls. Serum and saliva immune response to A. actinomycetemcomitans, its concentration in saliva, and serotype-distribution were examined. LPS-NC values ranged between 51-83% in the whole population. Although several of the LPS-NC determinants differed significantly between cases and controls (PLTP, sCD14, apoA-I, HDL-cholesterol), the levels did not (p = 0.056). The main determinants of LPS-NC were i) triglycerides (β = -0.68, p<0.001), and ii) HDL cholesterol (0.260, <0.001), LDL cholesterol (-0.265, <0.001), PLTP (-0.196, 0.011), and IgG against A. actinomycetemcomitans (0.174, 0.011). Saliva A. actinomycetemcomitans concentration was higher [log mean (95% CI), 4.39 (2.35-8.19) vs. 10.7 (5.45-21) genomes/ml, p = 0.023) and serotype D more frequent (4 vs. 0%, p = 0.043) in cases than controls. Serotypeablity or serotypes did not, however, relate to the LPS-NC. Serum LPS-NC comprised low PLTP-activity, triglyceride and LDL cholesterol concentrations, as well as high HDL cholesterol and IgG against A. actinomycetemcomitans. The present findings let us to conclude that LPS-NC did not associate with stroke.

Identifiants

pubmed: 32084157
doi: 10.1371/journal.pone.0228806
pii: PONE-D-19-30948
pmc: PMC7034831
doi:

Substances chimiques

Lipopolysaccharides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0228806

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Innate Immun. 2008 Aug;14(4):247-53
pubmed: 18669610
Infect Immun. 2003 Sep;71(9):5005-11
pubmed: 12933843
Crit Rev Clin Lab Sci. 2016;53(3):197-215
pubmed: 26732012
J Clin Periodontol. 2011 May;38(5):405-11
pubmed: 21362013
J Clin Microbiol. 1985 Jun;21(6):865-8
pubmed: 4008617
Atherosclerosis. 2001 Apr;155(2):297-305
pubmed: 11254899
Alcohol Clin Exp Res. 2001 Feb;25(2):261-8
pubmed: 11236841
J Periodontol. 2002 Jan;73(1):73-8
pubmed: 11846202
J Neuroimmunol. 2016 Aug 15;297:76-80
pubmed: 27397079
Int J Mol Sci. 2019 Feb 15;20(4):
pubmed: 30781342
Diabetes Care. 2011 Feb;34(2):392-7
pubmed: 21270197
Arch Intern Med. 2006 Mar 13;166(5):554-9
pubmed: 16534043
Acta Diabetol. 2015 Apr;52(2):395-404
pubmed: 25326898
Atherosclerosis. 2016 Nov;254:117-123
pubmed: 27728851
J Clin Periodontol. 2013 Jun;40(6):583-90
pubmed: 23521427
Crit Care Med. 2003 May;31(5):1359-66
pubmed: 12771603
Crit Care Med. 2003 Jun;31(6):1647-53
pubmed: 12794399
Infect Immun. 2000 May;68(5):2410-7
pubmed: 10768924
Nutr Rev. 2015 Jun;73(6):376-85
pubmed: 26011912
Innate Immun. 2010 Feb;16(1):39-47
pubmed: 19567486
Eur J Biochem. 1996 Dec 15;242(3):682-8
pubmed: 9022697
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12040-4
pubmed: 8265667
PLoS One. 2013 Jun 24;8(6):e67736
pubmed: 23826338
Diabetes Care. 2009 Sep;32(9):1689-93
pubmed: 19502539
Cerebrovasc Dis. 2005;20(4):226-32
pubmed: 16123541
Stroke. 2016 Jan;47(1):173-9
pubmed: 26604249
Curr Pharm Des. 2006;12(32):4229-45
pubmed: 17100625
Clin Microbiol Infect. 2004 Feb;10(2):98-118
pubmed: 14759235
Stroke. 2004 Sep;35(9):2020-3
pubmed: 15232116
Cerebrovasc Dis. 2009;27(6):608-13
pubmed: 19407444
Biochim Biophys Acta. 2001 Sep 28;1533(2):153-63
pubmed: 11566452
J Biol Chem. 2008 Jul 4;283(27):18702-10
pubmed: 18458077
J Am Coll Cardiol. 1999 Dec;34(7):1975-81
pubmed: 10588212
Thromb Res. 2017 Jun;154:19-25
pubmed: 28390251
J Biol Chem. 2011 Nov 4;286(44):38211-9
pubmed: 21896489
Curr Opin Lipidol. 1996 Apr;7(2):88-93
pubmed: 8743901
J Biol Chem. 1999 Nov 26;274(48):34116-22
pubmed: 10567381
Metabolism. 2013 May;62(5):661-8
pubmed: 23218923
Innate Immun. 2014 Jul;20(5):511-8
pubmed: 24045341
Infect Immun. 2001 May;69(5):2821-8
pubmed: 11292694
Sci Rep. 2016 Feb 09;6:20845
pubmed: 26857615
Scand J Immunol. 1997 Sep;46(3):242-5
pubmed: 9315111
Atherosclerosis. 2012 Aug;223(2):478-84
pubmed: 22704805
Diabetes. 2007 Jul;56(7):1761-72
pubmed: 17456850
J Lipid Res. 2004 Dec;45(12):2303-9
pubmed: 15342679
Infect Immun. 1991 Oct;59(10):3451-62
pubmed: 1716610
Innate Immun. 2009 Aug;15(4):195-204
pubmed: 19586997
Proteome Sci. 2011 Jun 28;9(1):34
pubmed: 21711511
Eur J Oral Sci. 2018 Oct;126 Suppl 1:26-36
pubmed: 30178551
J Endotoxin Res. 2003;9(2):113-8
pubmed: 12803885
Diabetes Care. 2011 Aug;34(8):1809-15
pubmed: 21636801
J Leukoc Biol. 2016 Oct;100(4):687-698
pubmed: 27418356
J Clin Endocrinol Metab. 2014 Jul;99(7):E1245-53
pubmed: 24694333
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Eur J Biochem. 1991 Sep 15;200(3):775-81
pubmed: 1915349
Cerebrovasc Dis. 2012;33(1):69-75
pubmed: 22133999
Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1433-9
pubmed: 17363692
J Clin Periodontol. 2018 Apr;45(4):413-421
pubmed: 29385645
Methods. 2005 Jun;36(2):97-101
pubmed: 15893933
J Clin Periodontol. 2017 Aug;44(8):784-792
pubmed: 28556187
PLoS One. 2018 Mar 22;13(3):e0193815
pubmed: 29565987
J Lipid Res. 2004 Jan;45(1):139-47
pubmed: 13130123
Bull World Health Organ. 1976;54(5):533-40
pubmed: 1088403
Sci Rep. 2017 Jun 8;7(1):3053
pubmed: 28596518
Innate Immun. 2011 Feb;17(3):327-37
pubmed: 20501516
Atherosclerosis. 2018 Feb;269:138-143
pubmed: 29353229

Auteurs

Jaakko Leskelä (J)

Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.

Milla Pietiäinen (M)

Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.

Anton Safer (A)

Institute of Global Health, University of Heidelberg, Heidelberg, Germany.

Markku Lehto (M)

Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.

Jari Metso (J)

Minerva Foundation Institute for Medical Research, Helsinki, Finland.

Ernst Malle (E)

Division of Molecular Biology and Biochemistry, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria.

Florian Buggle (F)

Department of Neurology, Klinikum Ludwigshafen, Ludwigshafen, Germany.

Heiko Becher (H)

University Medical Center Hamburg-Eppendorf, Institute of Medical Biometry and Epidemiology, Hamburg, Germany.
University Hospital Heidelberg, Institute of Global Health, Heidelberg, Germany.

Jouko Sundvall (J)

National Institute for Health and Welfare, Helsinki, Finland.

Armin J Grau (AJ)

Department of Neurology, Klinikum Ludwigshafen, Ludwigshafen, Germany.

Pirkko J Pussinen (PJ)

Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.

Frederick Palm (F)

Department of Neurology, Helios Klinikum Schleswig, Schleswig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH